Clinical trial
A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Skin Cancer
NCT02097875 is registered in ClinicalTrials.gov with Blaze Bioscience Australia Pty Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Skin Cancer
- Lead sponsor
- Blaze Bioscience Australia Pty Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2013
- Completion date
- March 31, 2015
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.